140 related articles for article (PubMed ID: 20137125)
1. [Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors].
Shan XY; Chen BA; Xia GH; Xu WL; Ding JH; Gao C; Sun YY; Wang J; Cheng J; Zhao G; Bao W; Song HH; Gao F; Wang F; Wang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):90-5. PubMed ID: 20137125
[TBL] [Abstract][Full Text] [Related]
2. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line.
Chen BA; Shan XY; Chen J; Xia GH; Xu WL; Schmit M
Chin J Cancer; 2010 Jun; 29(6):591-5. PubMed ID: 20507731
[TBL] [Abstract][Full Text] [Related]
3. [Inducing apoptosis and reversal effect of nilotinib in combination with tetrandrine on multidrug resistance of K562/A02 cell line].
Cui TY; Chen BA; Ding JH; Gao C; Cheng J; Bao W; Zhong YJ; Shan XY; Gao F; Xia GH; Schmitt A; Schmitt M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):28-33. PubMed ID: 21362216
[TBL] [Abstract][Full Text] [Related]
4. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H
Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954
[TBL] [Abstract][Full Text] [Related]
5. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
[TBL] [Abstract][Full Text] [Related]
6. [Study on reversal effect of nilotinib in combination with 5-BrTet on multidrug resistance of K562/A02 cell line].
Chen BA; Shan XY; Chen J; Wang F; Ding JH; Gao C; Zhao G; Wang XM; Xu WL; Gao F; Xia GH; Schmitt M
Zhonghua Xue Ye Xue Za Zhi; 2010 Jun; 31(6):385-8. PubMed ID: 21122353
[TBL] [Abstract][Full Text] [Related]
7. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells.
Chen BA; Mao PP; Cheng J; Gao F; Xia GH; Xu WL; Shen HL; Ding JH; Gao C; Sun Q; Chen WJ; Chen NN; Liu LJ; Li XM; Wang XM
Int J Nanomedicine; 2010 Aug; 5():437-44. PubMed ID: 20957165
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
Peng XX; Tiwari AK; Wu HC; Chen ZS
Chin J Cancer; 2012 Feb; 31(2):110-8. PubMed ID: 22098951
[TBL] [Abstract][Full Text] [Related]
10. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
[TBL] [Abstract][Full Text] [Related]
11. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
[TBL] [Abstract][Full Text] [Related]
12. [Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02].
Yin L; Chen BA; Cheng J; Ding JH; Gao C; Sun YY; Wang J; Zhao G; Gao F; Song HH; Bao W; Wu WW; Wang F; Liang YQ; Xia GH; Wang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):79-84. PubMed ID: 20137123
[TBL] [Abstract][Full Text] [Related]
13. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Morinaga K; Yamauchi T; Kimura S; Maekawa T; Ueda T
Int J Cancer; 2008 Jun; 122(11):2621-7. PubMed ID: 18338755
[TBL] [Abstract][Full Text] [Related]
14. [Effect of cyclosporine A, raloxifene and their combination on the reversion of multidrug resistance of K562/A02 line].
Bao W; Chen BA; Gao F; Ding JH; Xu WL; Sheng HL; Gao C; Sun YY; Chen J; Wang J; Zhao G; Ma Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):895-9. PubMed ID: 17096884
[TBL] [Abstract][Full Text] [Related]
15. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
Zhong J; Zhang J; Yu X; Zhang X; Dian L
Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
[TBL] [Abstract][Full Text] [Related]
16. [Effects of arsenic trioxide on expressions of vascular endothelial growth factor and P-glycoprotein in multidrug resistant leukemia cell line K562/A02].
Liang H; Zhang Y; Zhang JD; Gu J; Ma L; Wang XL; Shen WG
Zhong Xi Yi Jie He Xue Bao; 2007 Nov; 5(6):647-50. PubMed ID: 17997939
[TBL] [Abstract][Full Text] [Related]
17. Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells.
Cheng J; Wu W; Chen BA; Gao F; Xu W; Gao C; Ding J; Sun Y; Song H; Bao W; Sun X; Xu C; Chen W; Chen N; Liu L; Xia G; Li X; Wang X
Int J Nanomedicine; 2009; 4():209-16. PubMed ID: 19918367
[TBL] [Abstract][Full Text] [Related]
18. [Study on reversing mechanism of multidrug resistance of K562/A02 cell line by carnosic acid].
Yu XN; Li H; Chen XL; Li XX; Wang R; Gao F
Zhonghua Xue Ye Xue Za Zhi; 2010 Jun; 31(6):381-4. PubMed ID: 21122352
[TBL] [Abstract][Full Text] [Related]
19. [Effect of hypoxia inducible factor1-α inhibitor on reversal of multidrug resistance of K562/A02 cell line].
Chen BA; Wang F; Cheng J; Ding JH; Gao C; Sun YY; Wang J; Zhao G; Bao W; Song HH; Gao F; Xia GH; Shan XY
Zhonghua Xue Ye Xue Za Zhi; 2010 Jun; 31(6):389-93. PubMed ID: 21122354
[TBL] [Abstract][Full Text] [Related]
20. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
Eadie LN; Saunders VA; Hughes TP; White DL
Leuk Lymphoma; 2013 Mar; 54(3):569-78. PubMed ID: 22845311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
